A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
Yuxiang Ma, Yunpeng Yang, Yan Huang...
https://pubmed.ncbi.nlm.nih.gov/40082695/Actively Recruiting
Led by MediLink Therapeutics (Suzhou) Co., Ltd. · Updated on 2026-06-22
312
Participants Needed
45
Research Sites
26 weeks
Total Duration
Researchers are conducting a phase 1, multicenter, nonrandomized, open-label study to evaluate YL201 in patients with advanced solid tumors that have not responded to current treatments or lack standard therapy options. The study includes two parts Part 1 focuses on finding the maximum tolerated dose and recommended dose levels through dose escalation, while Part 2 enrolls patients with selected tumor types to further assess safety and efficacy of YL201. Participants will receive YL201 as an intravenous infusion once every three weeks in cycles. Some patients may receive YL201 alone at different dosages or in combination with atezolizumab during each 21-day cycle. Part 1 involves dose escalation cohorts to determine appropriate dosing, followed by Part 2 dose expansion cohorts to better define safety and evaluate treatment responses. Throughout the study, participants undergo tumor evaluations using RECIST criteria, laboratory tests, and safety monitoring to track adverse events, dose-limiting toxicities, and pharmacokinetics. For prostate cancer patients, prostate-specific antigen response and progression-free survival will be measured. The study lasts approximately 36 months, with ongoing assessments of tumor response, survival, and laboratory abnormalities conducted at regular intervals.
CONDITIONS
A Study of YL201 in Patients With Advanced Solid Tumors
S
Sasha Stann
A
Alan Xu, Ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
MediLink Therapeutics (Suzhou) Co., Ltd.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | YL201 intravenous every 3 weeks (with or without atezolizumab) | Current guideline-based systemic therapies (chemotherapy, targeted agents, or immunotherapies) |
|---|---|---|
| What is it? | YL201 is an investigational antibody-drug conjugate, delivered by intravenous infusion every 3 weeks. Participants may receive YL201 alone or in combination with atezolizumab. The study includes dose escalation and expansion to evaluate safety and effectiveness in adults with advanced solid tumors. | Guideline-recommended systemic therapies for advanced solid tumors typically include chemotherapy, targeted drugs, immunotherapy, or combinations, tailored to the tumor type and prior treatments. These are established approaches used outside investigational studies for patients who meet similar criteria. |
| Role in the study | YL201 is the main investigational therapy assessed for safety, tolerability, and preliminary effectiveness in previously treated or untreatable advanced solid tumor patients. | Systemic therapies are established treatments commonly offered to similar patients as part of routine clinical care outside clinical trials. |
| Primary use | YL201 is being evaluated for its ability to control tumor growth, reduce disease burden, and determine the safe dosage range in adults with advanced solid tumors. | Current-care systemic therapies are used to manage tumor progression, provide symptom relief, and extend survival in patients with advanced disease. |
| How is it given? | YL201 is given by intravenous infusion once every 3 weeks, with dosing adjustments based on safety and tolerability. In some cohorts, atezolizumab is also administered intravenously every 21-day cycle. | Systemic therapies are usually given by intravenous infusion, oral tablets, or injections; administration varies depending on the chosen regimen and tumor type. |
| Evidence status | Clinical evidence for YL201 is limited to ongoing study data and early-phase published research. Safety and effectiveness are still being actively evaluated and are not yet established for broader clinical use. | Guideline-based therapies have a robust evidence foundation from randomized clinical trials and are routinely used to improve progression-free survival, overall survival, and symptom control in advanced solid tumors. |
| Important limitations | YL201 is early in clinical development; most evidence is from dose-escalation and expansion cohorts. The full safety profile and long-term effectiveness remain unconfirmed, and many participants have previously received other treatments. | Standard systemic therapies may have limited effectiveness or tolerability for some patients, especially after multiple prior lines of treatment; not every patient is eligible for all regimens, and resistance can develop. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to several cycles as needed
Participants receive increasing doses of YL201 intravenously every 3 weeks to determine the maximum tolerated and recommended doses.
Visits every 3 weeks for each treatment cycle
Duration - Up to 36 months
Participants receive YL201 at the selected dose alone or combined with atezolizumab every 3 weeks to further evaluate safety and treatment response.
Regular visits every 3 weeks during treatment cycles
Duration - Up to 36 months
Participants are monitored for safety, adverse events, and treatment outcomes after completing treatment cycles.
Periodic visits as scheduled
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Yuxiang Ma, Yunpeng Yang, Yan Huang...
https://pubmed.ncbi.nlm.nih.gov/40082695/MediLink Therapeutics (Suzhou) Co., Ltd.
Lead Sponsor